The trial’s primary goal is to assess the percentage of patients with AKI within seven days after on-pump cardiac surgery. Credit: Natali _ Mis / Shutterstock.

Canadian clinical trial company Arch Biopartners has dosed the first patient in Canada in its Phase II clinical trial of LSALT peptide (Metablok) for preventing and treating cardiac surgery-associated acute kidney injury (CS-AKI).

The University of Calgary Cumming School of Medicine’s clinical team has begun screening trial subjects and dosed the first subject in Calgary, Alberta.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

The multicentre, international, randomised, double-blind, placebo-controlled trial will evaluate the drug candidate versus placebo.

It aims to recruit 240 participants, with 120 patients each to be randomised into the LSALT peptide or placebo arms.

The trial’s primary goal is to assess the percentage of patients with acute kidney injury within seven days of on-pump cardiac surgery, in line with the Kidney Disease: Improving Global Outcomes (KDIGO) criteria.

Participants will be monitored for safety and efficacy until day 28, with day one regarded as the day of subject randomisation and the study drug administration at least one hour before the induction of anaesthaesia.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

An independent Data and Safety Monitoring Board (DSMB) will evaluate patient data, focusing primarily on safety assessments.

LSALT peptide works by targeting the dipeptidase-1 (DPEP1) pathway. Its potential in preventing ischaemia-reperfusion injury to the kidneys was demonstrated in pre-clinical models.

Arch Biopartners CEO Richard Muruve said: “We are happy to see the team at the University of Calgary Hospital recruit and dose the first patient in Canada for our Phase II study targeting CS-AKI.

“Our five clinical sites in Turkey have made good recruitment progress and have done a great job executing the trial to date.

“The start of recruitment in Calgary, followed by the activation into the study of the two Toronto hospitals, will significantly boost the momentum of the trial.”

In addition to Canada, Arch Biopartners has also begun recruiting and dosing subjects in Turkey for the Phase II trial of LSALT peptide.